Plasma fractionation is a process of separating various components of plasma, which in turn is a component of blood obtained through blood fractionation. Plasma is separated and can be used for many different medical applications. Plasma is taken from donors when whole blood is donated, or by plasmapheresis - a process by which the liquid part of the blood, or plasma, is separated from the blood cells and plasma is retained. This plasma can be used as Fresh Frozen Plasma (FFP) for replacement of clotting factors. Most plasma is used for products which derived from plasma fractionation. Plasma comprehends thousands of diverse proteins, but only about 20 of these are used to produce therapeutic plasma products. These fit into three classes’ immunoglobulins, clotting factors, and albumin.

Download Free PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/529

Growth of this market is mainly attributed to increasing incidence of bleeding and immune disorders, growing geriatric population, and growing use of immunoglobulin and alpha-1-antitrypsin. Plasma fractionation is used for treating protein deficiency in healthcare applications and also as a packaging material for industrial applications. The prime function of plasma fractionation is removal or inactivation of viruses and prions.

According to Centers of Disease Control (CDC) statistic, in 2012 chronic diseases were one of the major causes of death and disability in the U.S., with an estimated 117 million people suffering from some form of chronic disease. Developed diagnostic facilities, and comfort of access to healthcare along with increasing incidence and prevalence of chronic diseases all over the world, are some factors responsible for the rising demand for plasma derived products and is expected to drive the plasma fractionation market during the forecast period. The increase in geriatric population all over world is an important factor for plasma fractionation market, mainly due to the risk of complications of hemophilia, such as intracranial hemorrhage, inhibitor development, and joint diseases, increases along with the age of a person.

North America is leading the global plasma fractionation market, owing to growing per capita healthcare spending in the U.S. And also rising demands from patients for better and advanced healthcare facilities, and increased acceptance of new and advanced technologies. Asia Pacific region is also witnessing highest CAGR in the forecast period, due to factors such as increasing prevalence of hemophilia among developing countries such as China, and India, and increasing aging population in the Asia Pacific region.

Global Key Klayers - Plasma Fractionation Market

Key players operating in the global plasma fractionation market are CSL Ltd., Octapharma AG, Grifols S.A, Baxalta Incorporated, Octapharma AG, and Kedrion S.p.A held the major share of the plasma fractionation market and will continue to take over the market. Other major players are Bio Products Laboratory, Sanquin, China Biologic Products, Inc., Biotest AG, and Laboratoire Français du Fractionnement et des Biotechnologies.

Browse Complete Research Report @ https://www.coherentmarketinsights.com/ongoing-insight/plasma-fractionation-market-529

Plasma Fractionation Market

On the basis of product type, the global plasma fractionation market is classified into:

• Albumin

• Immunoglobulins

• Coagulation Factor Concentrates

On the basis of application, the global plasma fractionation market is classified into:

• Neurology

• Hematology

• Immunology

• Critical Care

On the basis of end user, the global plasma fractionation market is classified into:

• Hospitals

• Clinical Research Laboratories

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave,

#3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Plasma Fractionation Market: Market Growth, Size, Share, Trends, Key Players, Competitive Intelligence 2013 to 2017 and Forecast 2018 to 2024

Plasma Fractionation Market report offers Market Size, Dynamics, Regional Market Share, Top Key Players, Latest trends, Growth factors, Industry Stats, Historic Market, Business Intelligence, Business Research Reports, Competitive Intelligence 2013 to 2017 and Forecast 2018 to 2024

 Plasma fractionation market expected to grow at significant rate over the forecast period due to rise in the incidence of immune and bleeding disorders, increase in the use of alpha-1 antitrypsin and immunoglobulin, rise in prevalence of Alpha-1 Antitrypsin Deficiency (AATD), emphysema, and haemophilia. In addition, development in plasma techniques and plasma utilization are the key factors expected to boost the plasma fractionation market. However, high cost for the plasma products, adverse effects associated with the plasma fractionation products, lack of reimbursement policies, stringent regulatory policies, and increase in the recombinant coagulation factors might hinder the growth of plasma fractionation market over the forecast timeframe.

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-plasma-fractionation-market/#ulp-4H8Z4LpNMLEuOnnx

Global plasma fractionation market segmented based on the product type, application, and end user

Based on product type, global plasma fractionation market segmented into the following:

• Albumin
• Immunoglobulin
  • Intravenous immunoglobulin
  • Subcutaneous immunoglobulin
  • Others
• Coagulation factor concentrates
  • Factor viii
  • Factor ix
  • Factor xiii
  • Prothrombin complex concentrates
  • Von Willebrand factor (VWF)
• Protease inhibitors
• Other plasma fractionation products

Based on application, global plasma fractionation market segmented into the following:

• Neurology
• Haematology
• Immunology
• Rheumatology
• Haemato-oncology
• Critical Care
• Pulmonology
• Others

Based on end-user, global plasma fractionation market segmented into the following:

• Hospitals
• Clinics
• Academic Institutes
• Clinical Research Laboratories

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-plasma-fractionation-market/#ulp-c654SbFYO64MsOhu

Several international players are actively involved in the development of global plasma fractionation products. In 2015, immunoglobulins commanded for the largest share of the global plasma fractionation market due to rise in prevalence and incidence autoimmune disorders (according to International Journal of Celiac Disease, 2015 the world prevalence and incidence of Autoimmune Diseases are increasing, the global net percent increased per year prevalence and incidence of autoimmune disorders were 12.5±7.9 and 19.1±43.1 respectively). However, the protease inhibitors are expected to highest growth in the forecasting period, due to increasing use of proteases for respiratory diseases and growing application in various diseases. Partnerships, agreements, new products launch, collaborations, acquisitions and mergers, joint ventures, are being adopted by various key players in the global plasma fractionation market. For instance, in 2003, Probitas Pharma acquired Alpha Therapeutic from Mitsubishi Pharma, similarly, Octapharma acquired Mexican fractionator Probifasa S.A. de C.V. for developing the plasma products.

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-plasma-fractionation-market/#ulp-14mlyhjMGhVjZqa3

Geographically, global plasma fractionation market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the global plasma fractionation market followed by Europe and Asia-Pacific. The largest share of North-America in global plasma fractionation market is due to increasing use of immunoglobulins in neurological diseases and increasing use of prophylaxis treatments for chronic diseases in this region (According to Centres of Disease Control (CDC), in 2012, chronic diseases were one of the leading causes of death and disability in the U.S., with an estimated 117 Mn adults suffering from some form of chronic disease). Europe is the second largest region for global plasma fractionation market due to the rise in aging population and increase in the prevalence of chronic diseases. However, Asia-Pacific is expected to register significant growth rate over the forecast owing to the increasing aging population, growing using of albumin and immunoglobulin, and an increasing focus on better diagnosis, prophylactic treatments, medical research, and organ transplantations in Asia-Pacific regions.

Some of the players in plasma fractionation market are Grifols S.A (Spain), CSL Ltd. (Australia), Shire (Ireland), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), China Biologic Products, Inc. (China), Biotest AG (OGEL GmbH) (Germany), LFB S.A (France), and Sanquin (Netherlands) to name a few.

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-plasma-fractionation-market/

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Precision Business Insights mission is to provide high-quality market research reports and generate key insights to our clients. PBI’s approachable strategies are to help clients to make key decisions for business growth.

Precision Business Insights vision is to become most valued partner to fortune 500 companies by providing agile, accurate, and actionable market insights

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com